Adult patients aged 18 years or older with type 2 diabetes who initiated SGLT2is were identified and compared with those who initiated dipeptidyl peptidase 4 inhibitors (DPP-4is) or glucagon-like peptide 1 receptor agonists (GLP-1RAs) using a propensity score–matched, active-comparator, new-user cohort design. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.